REG - Fusion Antibodies - Holding(s) in Company

Fusion AntibodiesAnnouncement

11/01/2022 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220111:nRSK1085Ya&default-theme=true

RNS Number : 1085Y  Fusion Antibodies PLC  11 January 2022

Fusion Antibodies plc

("Fusion" or the "Company")

 

Holdings in Company

 

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and diagnostic
applications, has today been advised that, following a share sale of 6,000
ordinary shares of 4p each in the Company ("Ordinary Shares") on 13 August
2021, Paul Warwick held 1,030,363 Ordinary Shares on that date, representing
3.98 per cent. of the Company's issued share capital at that time*.

 

*Based on the Company's then issued share capital of 25,871,612 Ordinary
Shares as at 13 August 2021.

 

Enquiries:

 

 Fusion Antibodies plc                             www.fusionantibodies.com (http://www.fusionantibodies.com)
 Richard Jones, Chief Executive Officer            Via Walbrook PR

 James Fair, Chief Financial Officer

 Allenby Capital Limited                           Tel: +44 (0)20 3328 5656
 James Reeve / Vivek Bhardwaj (Corporate Finance)

 Tony Quirke (Sales and Corporate Broking)

 Walbrook PR                                       Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
                                                   (mailto:fusion@walbrookpr.com)
 Anna Dunphy                                       Mob: +44 (0)7876 741 001
 Paul McManus                                      Mob: +44 (0)7980 541 893

 

About Fusion Antibodies plc

 

Fusion is a Belfast based contract research organisation ("CRO") providing a
range of antibody engineering services for the development of antibodies for
both therapeutic drug and diagnostic applications.

 

The Company's ordinary shares were admitted to trading on AIM on 18 December
2017. Fusion provides a broad range of services in antibody generation,
development, production, characterisation and optimisation. These services
include antigen expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary CDRx (TM) platform and the
production of antibody generating stable cell lines to provide material for
use in clinical trials. Since 2012, the Company has successfully sequenced
and expressed over 250 antibodies and successfully completed over 200
humanisation projects and has an international, blue-chip client base, which
has included eight of the top 10 global pharmaceutical companies by revenue.

 

The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and diagnostic
companies to develop innovative products in a timely and cost-effective manner
for the benefit of the global healthcare industry. Fusion Antibodies provides
a broad range of services in antibody generation, development, production,
characterisation and optimisation.

 

Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new platforms that
will enable Pharma and Biotech companies get to the clinic faster, with the
optimal drug candidate and ultimately speed up the drug development process.

 

The global monoclonal antibody therapeutics market was valued at $135.4
billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase
at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the
world's ten top selling drugs were antibody-based therapeutics with the
combined annual sales of these drugs exceeding $63.2 billion.

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  HOLGPUAPGUPPGWG